BIOXCEL THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.75 USD | +7.84% |
|
-5.17% | -6.78% |
Financials (USD)
| Sales 2024 * | 3.5M | Sales 2025 * | 9.13M | Capitalization | 102M |
|---|---|---|---|---|---|
| Net income 2024 * | -105M | Net income 2025 * | -78M | EV / Sales 2024 * | 64.9 x |
| Net Debt 2024 * | 125M | Net Debt 2025 * | 115M | EV / Sales 2025 * | 23.7 x |
| P/E ratio 2024 * |
-0.88
x | P/E ratio 2025 * |
-1.63
x | Employees | 74 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioXcel Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | +7.84% | ||
| 1 week | -5.17% | ||
| Current month | -2.48% | ||
| 1 month | +1.10% | ||
| 3 months | +7.00% | ||
| 6 months | +6.18% | ||
| Current year | -6.78% |
1 week
2.52
2.97
1 month
2.523.10
Current year
1.914.17
1 year
1.9129.56
3 years
1.9139.00
5 years
1.9171.50
10 years
1.9171.50
| Managers | Title | Age | Since |
|---|---|---|---|
Vimal Mehta
FOU | Founder | 63 | 17-03-28 |
| Director of Finance/CFO | 66 | 17-09-30 | |
Frank Yocca
CTO | Chief Tech/Sci/R&D Officer | 68 | 17-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Miller
BRD | Director/Board Member | 67 | 22-06-30 |
Peter Mueller
CHM | Chairman | 68 | 17-03-31 |
Sandeep Laumas
BRD | Director/Board Member | 56 | 17-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 9 M€ | +4.23% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 2.75 | +7.84% | 618,439 |
| 24-04-18 | 2.55 | -1.54% | 244,533 |
| 24-04-17 | 2.59 | -3.36% | 319,973 |
| 24-04-16 | 2.68 | -2.55% | 229,750 |
| 24-04-15 | 2.75 | -5.17% | 477,237 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Companyâs most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Calendar
2024-05-05
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
2.55
USD
Average target price
7.25
USD
Spread / Average Target
+184.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.78% | 77.97M | |
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B |
- Stock Market
- Equities
- BTAI Stock
